Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Actionable lung cancer targets

Stephen Liu • 30 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Capmatinib Crizotinib Larotrectinib Tepotinib

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, actionable targets for the treatment of non-small cell lung cancer (NSCLC), such as MET and RET. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Stephen Liu

1:41
Managing ALK+ NSCLC
Stephen Liu • 30 Jan 2020
2:09
ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC
Stephen Liu • 30 Jan 2020
1:30
A shifting paradigm: lung cancer
Stephen Liu • 30 Jan 2020
1:48
Stephen Liu: BTOG highlights
Stephen Liu • 30 Jan 2020

Related Videos

0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
4:20
Insights from BTOG 2024: advancements in TNM Staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals